



(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition.**

On August 9, 2016, Elite Pharmaceuticals, Inc. (the “Company”) filed its quarterly report on Form 10-Q for the quarter ended June 30, 2016 and, thereafter, issued a press release announcing its financial results for that quarter. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

As noted in the press release, the Company will host a conference call at 11:00 a.m. Eastern Daylight Time (EDT) on Thursday, August 11, 2016, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.

**Conference Call Information**

Date: Thursday, August 11, 2016

Time: 11:00 AM EDT

Dial-in numbers: 1-800-346-7359 (domestic)  
1-973-528-0008 (international)

Conference number: 98840

Questions: dianne@elitepharma.com by 6:00 PM EDT on Wednesday, August 10, 2016

Audio Replay: [http://ir.elitepharma.com/events\\_presentations](http://ir.elitepharma.com/events_presentations)

**Item 7.01 Regulation FD Disclosure.**

The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No. Description

99.1 Press Release dated August 9, 2016

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ELITE  
Dated: August 9, 2016 PHARMACEUTICALS,  
INC.

By: /s/ Nasrat Hakim  
Nasrat Hakim,  
President and CEO